GLS and gastritis: Previous studies have shown that GLS1 inhibitors like DON were discontinued in clinical development due to systemic toxicities, particularly GI issues such as nausea, gastritis, and diarrhea [[41], [42], [43]], as the GI system is highly dependent on glutamine metabolism [[83], [84], [85]].